ASH 2018: Highlights on rivaroxaban thromboprophylaxis in patients receiving anticancer therapy

Speaker: Alok Khorana

Reporting from ASH 2018, Alok Khorana explains that patients with solid tumours or lymphoma, at high risk for developing a blood clot according to the Khorana score but without a blood clot already present were randomised to rivaroxaban thromboprophylaxis or control arm. Compliance was not good after a few months, but the analysis demonstrated a significant reduction of blood clots occurrence in the treatment arm. In addition the treatment arm showed a significantly better survival at 6 month, all cause mortality included. The occurrence of major or non-major bleeding was relatively low but still a concern for prevention treatment. A second ongoing trial on the same question may confirm the benefit of thromboprophylaxis in this high risk population.

ASH 2018 abstract:

LBA-1 Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI) ; Alok Khorana